Page 2194 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 2194

1943.e4  Part XII  Hemostasis and Thrombosis


            required  for  platelet  adhesion  and  activation.  J  Exp  Med  196:1057,   178.  Berndt MC, Kabral A, Grimsley P, et al: An acquired Bernard-Soulier-
            2002.                                                 like platelet defect associated with juvenile myelodysplastic syndrome.
        154.  Munday  AD,  Gaus  K,  Lopez  JA: The  platelet  glycoprotein  Ib-IX-V   Br J Haematol 68:97, 1988.
            complex anchors lipid rafts to the membrane skeleton: implications for   179.  Cooper B, Schafer AI, Puchalsky D, et al: Platelet resistance to prosta-
            activation-dependent cytoskeletal translocation of signaling molecules.   glandin D2 in patients with myeloproliferative disorders. Blood 52:618,
            J Thromb Haemost 8:163, 2010.                         1978.
        155.  Liao JK: Isoprenoids as mediators of the biological effects of statins.     180.  Horikawa  Y,  Matsumura  I,  Hashimoto  K,  et al:  Markedly  reduced
            J Clin Invest 110:285, 2002.                          expression  of  platelet  c-mpl  receptor  in  essential  thrombocythemia.
        156.  Heeschen C, Hamm CW, Laufs U, et al: Withdrawal of statins increases   Blood 90:4031, 1997.
            event  rates  in  patients  with  acute  coronary  syndromes.  Circulation   181.  Moore A, Nachman RL: Platelet Fc receptor. Increased expression in
            105:1446, 2002.                                       myeloproliferative disease. J Clin Invest 67:1064, 1981.
        157.  Hackam DG, Woodward M, Newby LK, et al: Statins and intracerebral   182.  Toyama  K,  Karasawa  M,  Yamane  A,  et al:  JAK2-V617F  mutation
            hemorrhage: collaborative systematic review and meta-analysis. Circula-  analysis of granulocytes and platelets from patients with chronic myelo-
            tion 124:2233, 2011.                                  proliferative disorders: advantage of studying platelets. Br J Haematol
        158.  Callahan KP, Malinin AI, Atar D, et al: Platelet activation as a universal   139:64, 2007.
            trigger in the pathogenesis of acute coronary events after cocaine abuse.   183.  Falanga A, Marchetti M, Vignoli A, et al: V617F JAK-2 mutation in
            Swiss Med Wkly 131:487, 2001.                         patients with essential thrombocythemia: relation to platelet, granulo-
        159.  Jennings LK, White MM, Sauer CM, et al: Cocaine-induced platelet   cyte, and plasma hemostatic and inflammatory molecules. Exp Hematol
            defects. Stroke 24:1352, 1993.                        35:702, 2007.
        160.  Hobbs WE, Moore EE, Penkala RA, et al: Cocaine and specific cocaine   184.  Panova-Noeva  M, Marchetti  M,  Spronk HM,  et al: Platelet-induced
            metabolites induce von Willebrand factor release from endothelial cells   thrombin generation by the calibrated automated thrombogram assay is
            in a tissue-specific manner. Arterioscler Thromb Vasc Biol 33:1230, 2013.  increased in patients with essential thrombocythemia and polycythemia
        161.  Dyerberg J, Bang HO: Haemostatic function and platelet polyunsatu-  vera. Am J Hematol 86:337, 2011.
            rated fatty acids in Eskimos. Lancet 2:433, 1979.  185.  Castaman G, Lattuada A, Ruggeri M, et al: Platelet von Willebrand
        162.  Kim  DN,  Eastman  A,  Baker  JE,  et al:  Fish  oil,  atherogenesis,  and   factor  abnormalities  in  myeloproliferative  syndromes.  Am  J  Hematol
            thrombogenesis. Ann N Y Acad Sci 748:474, 1995.       49:289, 1995.
        163.  Schoene NW: Vitamin E and omega-3 fatty acids: effectors of platelet   186.  van Genderen PJ, Leenknegt H, Michiels JJ: The paradox of bleeding
            responsiveness. Nutrition 17:793, 2001.               and thrombosis in thrombocythemia: is von Willebrand factor the link?
        164.  Deykin  D,  Janson  P,  McMahon  L:  Ethanol  potentiation  of  aspirin-  Semin Thromb Hemost 23:385, 1997.
            induced  prolongation  of  the  bleeding  time.  N  Engl  J  Med  306:852,   187.  van  Genderen  PJ,  Leenknegt  H,  Michiels  JJ,  et al:  Acquired  von
            1982.                                                 Willebrand  disease  in  myeloproliferative  disorders.  Leuk  Lymphoma
        165.  Rand  ML,  Jakubowski  JA,  Fisher  MJ,  et al:  Ethanol  enhances  the   22(Suppl 1):79–82, 1996.
            inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet   188.  van Genderen PJ, Budde U, Michiels JJ, et al: The reduction of large
            function. J Lab Clin Med 140:391, 2002.               von Willebrand factor multimers in plasma in essential thrombocythae-
        166.  Nguyen  A,  Packham  MA,  Rand  ML:  Effects  of  ethanol  on  platelet   mia is related to the platelet count. Br J Haematol 93:962, 1996.
            responses  associated  with  adhesion  to  collagen.  Thromb  Res  95:303,   189.  Tiede  A,  Rand  JH,  Budde  U,  et al:  How  I  treat  the  acquired  von
            1999.                                                 Willebrand syndrome. Blood 117:6777, 2011.
        167.  Hammerschmidt  DE:  Szechwan  purpura.  N  Engl  J  Med  302:1191,   190.  Shim  K,  Anderson  PJ, Tuley  EA,  et al:  Platelet-vWF  complexes  are
            1980.                                                 preferred  substrates  of  ADAMTS13  under  fluid  shear  stress.  Blood
        168.  Srivastava KC: Onion exerts antiaggregatory effects by altering arachi-  111:651, 2008.
            donic acid metabolism in platelets. Prostaglandins Leukot Med 24:43,   191.  Mohri  H,  Motomura  S,  Kanamori  H,  et al:  Clinical  significance  of
            1986.                                                 inhibitors in acquired von Willebrand syndrome. Blood 91:3623, 1998.
        169.  Apitz-Castro R, Badimon JJ, Badimon L: Effect of ajoene, the major   192.  Bessler M, Mason PJ, Hillmen P, et al: Paroxysmal nocturnal haemo-
            antiplatelet  compound  from  garlic,  on  platelet  thrombus  formation.   globinuria (PNH) is caused by somatic mutations in the PIG-A gene.
            Thromb Res 68:145, 1992.                              EMBO J 13:110, 1994.
        170.  Srivastava KC: Extracts from two frequently consumed spices–cumin   193.  Vu T, Griscelli-Bennaceur A, Gluckman E, et al: Aplastic anaemia and
            (Cuminum cyminum) and turmeric (Curcuma longa)–inhibit platelet   paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored
            aggregation and alter eicosanoid biosynthesis in human blood platelets.   proteins on human platelets. Br J Haematol 93:586, 1996.
            Prostaglandins Leukot Essent Fatty Acids 37:57, 1989.  194.  Fu R, Meng Y, Wang Y, et al: The dysfunction of platelets in paroxysmal
        171.  Kaur H, Corscadden K, Lott C, et al: Bromelain has paradoxical effects   nocturnal hemoglobinuria. Thromb Res 148:50, 2016.
            on  blood  coagulability:  a  study  using  thromboelastography.  Blood   195.  Steinberg D, Carvalho AC, Chesney CM, et al: Platelet hypersensitivity
            Coagul Fibrinolysis 27:745, 2016.                     and intravascular coagulation in paroxysmal nocturnal hemoglobinuria.
        172.  Chaves DS, Frattani FS, Assafim M, et al: Phenolic chemical composi-  Am J Med 59:845, 1975.
            tion of Petroselinum crispum extract and its effect on haemostasis. Nat   196.  Grunewald M, Grunewald A, Schmid A, et al: The platelet function
            Prod Commun 6:961, 2011.                              defect  of  paroxysmal  nocturnal  haemoglobinuria.  Platelets  15:145,
        173.  George JN, Shattil SJ: The clinical importance of acquired abnormali-  2004.
            ties of platelet function. N Engl J Med 324:27, 1991.  197.  Gralnick  HR,  Vail  M,  McKeown  LP,  et al:  Activated  platelets  in
        174.  Barbui T, Barosi G, Grossi A, et al: Practice guidelines for the therapy   paroxysmal nocturnal haemoglobinuria. Br J Haematol 91:697, 1995.
            of  essential  thrombocythemia.  A  statement  from  the  Italian  Society   198.  Lackner H, Hunt V, Zucker MB, et al: Abnormal fibrin ultrastructure,
            of Hematology, the Italian Society of Experimental Hematology and   polymerization, and clot retraction in multiple myeloma. Br J Haematol
            the  Italian  Group  for  Bone  Marrow  Transplantation.  Haematologica   18:625, 1970.
            89:215, 2004.                                     199.  Edelstein C, Scanu AM: Precautionary measures for collecting blood
        175.  Ashrani AA, Tefferi A, Pruthi RK, et al: Acquired factor V deficiency   destined for lipoprotein isolation. Methods Enzymol 128:151, 1986.
            in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients.   200.  Mehta J, Singhal S: Hyperviscosity syndrome in plasma cell dyscrasias.
            Br J Haematol 171:875, 2015.                          Semin Thromb Hemost 29:467, 2003.
        176.  Carobbio A, Thiele J, Passamonti F, et al: Risk factors for arterial and   201.  Kwaan HC: Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol
            venous  thrombosis  in  WHO-defined  essential  thrombocythemia:  an   Microcirc 55:75, 2013.
            international study of 891 patients. Blood 117:5857, 2011.  202.  Palmer  RN,  Rick  ME,  Rick  PD,  et al:  Circulating  heparan  sulfate
        177.  Ginsburg AD: Platelet function in patients with high platelet counts.   anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med
            Ann Intern Med 82:506, 1975.                          310:1696, 1984.
   2189   2190   2191   2192   2193   2194   2195   2196   2197   2198   2199